tetano
Editor, Senior Moderator
Heart Fail Clin
. 2023 Apr;19(2):251-264.
doi: 10.1016/j.hfc.2022.08.012.
Myocarditis Following COVID-19 Vaccination
Constantin A Marschner[SUP] 1 [/SUP], Kirsten E Shaw[SUP] 2 [/SUP], Felipe Sanchez Tijmes[SUP] 3 [/SUP], Matteo Fronza[SUP] 4 [/SUP], Sharmila Khullar[SUP] 5 [/SUP], Michael A Seidman[SUP] 5 [/SUP], Paaladinesh Thavendiranathan[SUP] 6 [/SUP], Jacob A Udell[SUP] 7 [/SUP], Rachel M Wald[SUP] 8 [/SUP], Kate Hanneman[SUP] 9 [/SUP]
Affiliations
Abstract
Myocarditis is an established but rare adverse event following administration of messenger RNA-based coronavirus disease 2019 (COVID-19) vaccines and is most common in male adolescents and young adults. Symptoms typically develop within a few days of vaccine administration. Most patients have mild abnormalities on cardiac imaging with rapid clinical improvement with standard treatment. However, longer term follow-up is needed to determine whether imaging abnormalities persist, to evaluate for adverse outcomes, and to understand the risk associated with subsequent vaccination. The purpose of the review is to evaluate the current literature related to myocarditis following COVID-19 vaccination, including the incidence, risk factors, clinical course, imaging findings, and proposed pathophysiologic mechanisms.
Keywords: COVID-19; Cardiac MRI; Myocarditis; Vaccine; mRNA vaccine.
. 2023 Apr;19(2):251-264.
doi: 10.1016/j.hfc.2022.08.012.
Myocarditis Following COVID-19 Vaccination
Constantin A Marschner[SUP] 1 [/SUP], Kirsten E Shaw[SUP] 2 [/SUP], Felipe Sanchez Tijmes[SUP] 3 [/SUP], Matteo Fronza[SUP] 4 [/SUP], Sharmila Khullar[SUP] 5 [/SUP], Michael A Seidman[SUP] 5 [/SUP], Paaladinesh Thavendiranathan[SUP] 6 [/SUP], Jacob A Udell[SUP] 7 [/SUP], Rachel M Wald[SUP] 8 [/SUP], Kate Hanneman[SUP] 9 [/SUP]
Affiliations
- PMID: 36863817
- DOI: 10.1016/j.hfc.2022.08.012
Abstract
Myocarditis is an established but rare adverse event following administration of messenger RNA-based coronavirus disease 2019 (COVID-19) vaccines and is most common in male adolescents and young adults. Symptoms typically develop within a few days of vaccine administration. Most patients have mild abnormalities on cardiac imaging with rapid clinical improvement with standard treatment. However, longer term follow-up is needed to determine whether imaging abnormalities persist, to evaluate for adverse outcomes, and to understand the risk associated with subsequent vaccination. The purpose of the review is to evaluate the current literature related to myocarditis following COVID-19 vaccination, including the incidence, risk factors, clinical course, imaging findings, and proposed pathophysiologic mechanisms.
Keywords: COVID-19; Cardiac MRI; Myocarditis; Vaccine; mRNA vaccine.